Online citations, reference lists, and bibliographies.
← Back to Search

Growth Hormone And Sex Steroid Administration In Healthy Aged Women And Men: A Randomized Controlled Trial.

M. Blackman, J. Sorkin, T. Münzer, M. Bellantoni, J. Busby‐Whitehead, T. E. Stevens, J. Jayme, K. G. O'Connor, C. Christmas, Jordan D. Tobin, K. Stewart, E. Cottrell, C. St Clair, K. Pabst, S. Harman
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
CONTEXT Hormone administration to elderly individuals can increase lean body mass (LBM) and decrease fat, but interactive effects of growth hormone (GH) and sex steroids and their influence on strength and endurance are unknown. OBJECTIVE To evaluate the effects of recombinant human GH and/or sex steroids on body composition, strength, endurance, and adverse outcomes in aged persons. DESIGN, SETTING, AND PARTICIPANTS A 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling US women (n = 57) and men (n = 74) aged 65 to 88 years recruited between June 1992 and July 1998. INTERVENTIONS Participants were randomized to receive GH (starting dose, 30 micro g/kg, reduced to 20 micro g/kg, subcutaneously 3 times/wk) + sex steroids (women: transdermal estradiol, 100 micro g/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10 days of each 28-day cycle [HRT]; men: testosterone enanthate, biweekly intramuscular injections of 100 mg) (n = 35); GH + placebo sex steroid (n = 30); sex steroid + placebo GH (n = 35); or placebo GH + placebo sex steroid (n = 31) in a 2 x 2 factorial design. MAIN OUTCOME MEASURES Lean body mass, fat mass, muscle strength, maximum oxygen uptake (VO(2)max) during treadmill test, and adverse effects. RESULTS In women, LBM increased by 0.4 kg with placebo, 1.2 kg with HRT (P =.09), 1.0 kg with GH (P =.001), and 2.1 kg with GH + HRT (P<.001). Fat mass decreased significantly in the GH and GH + HRT groups. In men, LBM increased by 0.1 kg with placebo, 1.4 kg with testosterone (P =.06), 3.1 kg with GH (P<.001), and 4.3 kg with GH + testosterone (P<.001). Fat mass decreased significantly with GH and GH + testosterone. Women's strength decreased in the placebo group and increased nonsignificantly with HRT (P =.09), GH (P =.29), and GH + HRT (P =.14). Men's strength also did not increase significantly except for a marginally significant increase of 13.5 kg with GH + testosterone (P =.05). Women's VO(2)max declined by 0.4 mL/min/kg in the placebo and HRT groups but increased with GH (P =.07) and GH + HRT (P =.06). Men's VO(2)max declined by 1.2 mL/min/kg with placebo and by 0.4 mL/min/kg with testosterone (P =.49) but increased with GH (P =.11) and with GH + testosterone (P<.001). Changes in strength (r = 0.355; P<.001) and in VO(2)max (r = 0.320; P =.002) were directly related to changes in LBM. Edema was significantly more common in women taking GH (39% vs 0%) and GH + HRT (38% vs 0%). Carpal tunnel symptoms were more common in men taking GH + testosterone (32% vs 0%) and arthralgias were more common in men taking GH (41% vs 0%). Diabetes or glucose intolerance occurred in 18 GH-treated men vs 7 not receiving GH (P =.006). CONCLUSIONS In this study, GH with or without sex steroids in healthy, aged women and men increased LBM and decreased fat mass. Sex steroid + GH increased muscle strength marginally and VO( 2)max in men, but women had no significant change in strength or cardiovascular endurance. Because adverse effects were frequent (importantly, diabetes and glucose intolerance), GH interventions in the elderly should be confined to controlled studies.
This paper references
10.1056/NEJM199308263290917
Growth hormone, insulin-like growth factor I, and benign intracranial hypertension.
S. Malozowski (1993)
10.1210/JCEM.86.5.7517
Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
V. Hayes (2001)
10.1001/JAMA.288.3.321
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
J. Rossouw (2002)
10.1172/JCI2773
The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
A. J. O’sullivan (1998)
10.1210/MEND.15.10.0708
New androgen response elements in the murine pem promoter mediate selective transactivation.
K. Barbulescu (2001)
10.1210/JCEM.75.4.1400877
Effects of testosterone supplementation in the aging male.
J. S. Tenover (1992)
10.1016/0026-0495(91)90037-W
Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause.
J. Haarbo (1991)
Studies in the distribution of body fat. II. Longitudinal effects of change in weight.
H. Shimokata (1989)
10.1093/AJCN/51.6.1106
Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition.
R. Mazess (1990)
10.1038/OBY.2001.81
Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy.
M. Sørensen (2001)
10.1007/978-1-4613-3994-6_16
Endocrinology and Aging
P. Davis (1978)
10.1210/JCEM.86.8.7773
Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men.
T. Münzer (2001)
10.1016/S0026-0495(98)90050-6
Insulin resistance and fat patterning with aging: relationship to metabolic risk factors for cardiovascular disease.
W. Cefalu (1998)
10.1016/S0895-4356(99)00049-9
The physical activity scale for the elderly (PASE): evidence for validity.
R. Washburn (1999)
10.1152/JAPPL.1997.83.5.1581
Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr.
R. Lindle (1997)
10.1016/S0140-6736(02)09519-3
Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study
A. Swerdlow (2002)
10.1210/JCEM.84.8.5885
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.
P. Snyder (1999)
10.1111/j.1532-5415.1999.tb05201.x
Once‐Weekly Resistance Exercise Improves Muscle Strength and Neuromuscular Performance in Older Adults
D. Taaffe (1999)
10.1054/GHIR.1999.0091
The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
A. Rosenfalck (1999)
10.1016/S0531-5565(99)00032-7
Theoretical basis for the benefit of postmenopausal estrogen substitution
M. Miller (1999)
10.1007/BF03340149
Effects of six-month administration of recombinant human growth hormone to healthy elderly subjects
C. Cuttica (1997)
10.7326/0003-4819-124-8-199604150-00002
Growth Hormone Replacement in Healthy Older Men Improves Body Composition but Not Functional Ability
M. Papadakis (1996)
10.1210/JCEM-72-1-172
Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
M. Bellantoni (1991)
10.1210/JCEM.87.2.8222
Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
A. Gentili (2002)
10.1210/JCEM.85.8.6731
Effects of testosterone replacement in hypogonadal men.
P. Snyder (2000)
10.1210/JCEM.79.5.7525633
Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men.
D. Taaffe (1994)
10.1093/GERONA/52A.3.M149
Successful 6-month endurance training does not alter insulin-like growth factor-I in healthy older men and women.
M. Vitiello (1997)
Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults.
D. Johnston (1999)
10.1159/000023531
Growth Hormone – Hormone Replacement for the Somatopause?
R. Savine (2000)
10.1093/GERONA/57.1.M12
Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men.
C. Christmas (2002)
10.1111/j.1365-2265.1993.tb02388.x
Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF‐I concentrations
L. Cohn (1993)
10.1002/JBMR.5650090107
Grip strength and bone mineral density in older women
D. Kritz-Silverstein (1994)
10.1210/JCEM.87.4.8362
Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women.
A. Dobs (2002)
10.1016/0002-8703(66)90210-9
Quantitation of QRS and ST segment responses to exercise.
R. Bruce (1966)
10.1001/JAMA.279.8.585
Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study.
L. Fried (1998)
10.1007/978-1-4612-1546-2_5
Influence of Testosterone on the GH—IGF-I Axis in Healthy Elderly Men
M. Blackman (1999)
10.1210/JCEM.86.9.7868
Association of IGF-I levels with muscle strength and mobility in older women.
A. Cappola (2001)
10.1210/JCEM.82.2.3733
Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.
S. Bhasin (1997)
10.2337/DIACARE.23.3.422
Long-term transdermal estrogen therapy improves lipid profile but not insulin resistance in healthy postmenopausal women.
A. Lasco (2000)
10.1001/JAMA.1980.03310210021018
Predominance of early endometrial cancers after long-term estrogen use.
B. Hulka (1980)
10.2337/diacare.25.2007.s5
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
J. Gavin (2003)
10.1093/GERONA/53A.3.M176
Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men.
K. G. O'Connor (1998)
10.1210/JCEM.83.2.4594
Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review
P. Carroll (1998)
10.1210/JCEM.86.2.7219
Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.
S. Harman (2001)
10.1507/ENDOCRJ.43.SUPPL_S57
Metabolic actions of growth hormone in man.
K. K. Ho (1996)
10.1210/JCEM.82.2.3776
Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
P. Burman (1997)



This paper is referenced by
10.1016/S2213-8587(16)30218-2
Use and misuse of hormones in sport.
P. Sőnksen (2016)
10.1097/01.AOG.0000138805.07080.5e
Body Mass Index and Insulin Resistance
C. Hammond (2004)
Endokrine Therapieoption in der Menopause: GH, Melatonin, DHEA etc.?
Joerg Bojunga (2012)
10.1136/bmj.328.7445.908
Refeeding syndrome
S. D. Hearing (2004)
The search for a treatment for ageing
BIOLOGICAL AGEING (2018)
Title Association of handgrip strength with chronic diseases andmultimorbidity-A cross-sectional study
Eleanor Au (2012)
10.1152/JAPPLPHYSIOL.00817.2004
Muscle strength response to strength training is influenced by insulin-like growth factor 1 genotype in older adults.
M. Kostek (2005)
10.1113/jphysiol.2009.179325
Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis
S. Doessing (2010)
10.1210/JC.2005-0275
A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
T. Storer (2005)
10.1300/J485v09n03_02
Transgender Primary Medical Care
J. Feldman (2006)
10.1007/978-1-4614-8492-9_7
Complementary and Alternative Medicine and Lifestyle Changes and Prostate Cancer
M. Moyad (2014)
Educação Médica Continuada Hormônios no rejuvenescimento: revisão de sua real eficácia Hormones in rejuvenation: a review of their true effectiveness
J. Antonio (2012)
10.7326/0003-4819-152-9-201005040-00007
The Effects of Growth Hormone on Body Composition and Physical Performance in Recreational Athletes
U. Meinhardt (2010)
10.1093/GERONA/58.10.M911
Sarcopenia: causes, consequences, and preventions.
T. Marcell (2003)
10.1177/039463200601900401
Sarcopenia: Age-Related Skeletal Muscle Changes from Determinants to Physical Disability
A. Di Iorio (2006)
10.1007/S00108-007-1842-9
[Doping. High-tech cheating in sport].
H. Striegel (2007)
10.1016/B978-1-4557-2758-2.00016-0
Chapter 16 – Male Reproductive Aging
Peter J. Snyder (2014)
Title: The Effects of Growth Hormone (GH) and /or Testosterone Administration on Whole Body Protein Kinetics and Skeletal Muscle Gene Expression in Healthy Elderly Men: A Randomised Controlled Trial
P. Sőnksen (2008)
10.1016/S1567-7443(04)80010-3
The Role of Growth Hormone Signaling in the Control of Ageing
A. Bartke (2004)
10.1111/j.1365-2265.2009.03683.x
Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF‐1 – implications for steroid‐induced myopathy
W. Inder (2010)
10.1001/JAMA.288.18.2333
Use it or lose it: activity may be the best treatment for aging.
C. Cassel (2002)
10.1016/j.pop.2017.04.006
Hormone Replacement: The Fountain of Youth?
B. Williams (2017)
10.1210/JC.2013-2025
Idiopathic growth hormone deficiency in adults, Ben Johnson and the somatopause.
P. Sönksen (2013)
10.1093/gerona/glr083
Effect of a combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice.
Katherine Forman (2011)
10.1016/j.steroids.2011.02.034
Pharmacology of arthralgia with estrogen deprivation
A. Lintermans (2011)
10.1210/jc.2011-2967
Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study.
R. Kaplan (2012)
Effects of long-term continuous positive airway pressure on body composition and IGF 1
T. Münzer (2010)
Oxidized LDL lipids as a risk factor for atherosclerosis
M. Linna (2014)
older adults influenced by insulin-like growth factor 1 genotype in Muscle strength response to strength training is
Larry W. Douglass (2015)
Histopathology in Skeletal Muscle of Transgenic Mice Suggests Dual-Locus of Onset (DLO) in Kennedy's Disease
Mike McPhail (2014)
10.1016/J.IJCME.2014.06.001
Cardiometabolic implication of sarcopenia: The Korea National Health and Nutrition Examination Study (KNHANES) 2008–2010
K. Kim (2014)
10.1016/J.GHIR.2007.04.011
Growth hormone action in puberty: effects by gender.
N. Mauras (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar